06 August 2026

Australia among the world's first countries to adopt a modern framework for prostate cancer early detection

Landmark national Guidelines harness 10 years of scientific progress to detect aggressive prostate cancer earlier while reducing unnecessary harm.

Download the PDF infographic on PSA testing

Download the Guideline summary document

Click here to learn more about free PSA testing in Australia.

Australia has become one of the first countries in the world to adopt a modern, evidence-based framework for the early detection of prostate cancer, with the release today of the 2026 Clinical Practice Guidelines for the Early Detection of Prostate Cancer in Australia.

Replacing the 2016 Guidelines, the new recommendations reflect more than a decade of advances in scientific evidence, diagnostic technology, and clinical practice.

Developed by Prostate Cancer Foundation of Australia and approved by the National Health and Medical Research Council, they establish a new national framework for risk assessment, shared decision-making, PSA testing, and contemporary diagnostic pathways designed to detect clinically significant prostate cancer earlier while reducing unnecessary tests and treatment.

The Guidelines position Australia among the world's first countries to transition from an informal model of discretionary testing to a planned, evidence-based approach to opportunistic early detection, reflecting one of the most significant advances in prostate cancer policy in more than a decade.

The review was one of the most comprehensive ever undertaken in Australian men's health, bringing together leading clinicians, researchers, consumers and policy experts from across Australia and internationally.

Over two years, the Guideline Steering Committee convened by PCFA examined more than 27,000 scientific abstracts, evaluated more than 1,100 published research papers and considered more than 1,400 submissions received through three rounds of public consultation.

Comments from PCFA's Chief of Mission and Head of Research

Professor Jeff Dunn AO, Chair of the Guideline Steering Committee, said the new Guidelines represented a watershed moment in Australia's approach to prostate cancer.

"These Guidelines represent the culmination of years of scientific work, national collaboration, and rigorous evaluation of the evidence.

"Much has changed over the past decade. The evidence has matured, diagnostic technologies have advanced, and clinical practice has evolved substantially.

"For the first time, Australia now has a contemporary national framework that better balances the benefits of detecting aggressive prostate cancer early with the need to minimise unnecessary harms.

"Our ambition is simple: to ensure every Australian man has access to the very best evidence available, giving him the greatest possible opportunity to detect clinically significant prostate cancer early, receive timely treatment where required, and ultimately reduce his risk of dying from this disease."

Comments from Chair of the Guideline Expert Advisory Panel 

Adjunct Professor Peter Heathcote, Chair of the Guideline Expert Advisory Panel, said advances in diagnosis had fundamentally changed the way clinicians investigate prostate cancer.

"Modern prostate cancer diagnosis is no longer based on a PSA blood test alone.

"Today's diagnostic pathway incorporates individual risk assessment, shared decision-making, multiparametric MRI before biopsy, targeted biopsy techniques, and active surveillance for men with low-risk disease.

"These advances allow clinicians to identify clinically significant cancers more accurately while reducing unnecessary biopsies, significantly reducing risks of overtreatment, and ensuring we protect men’s quality of life while managing individual risks."

The Guidelines include updated recommendations across every stage of early detection, including risk assessment, PSA testing, use of multiparametric MRI before biopsy, active surveillance and care for priority populations.

They also strengthen recommendations for men with significant family history, inherited genetic risk and other groups at increased risk of developing clinically significant prostate cancer.

Comments from PCFA's Chief Executive Officer

Prostate Cancer Foundation of Australia Chief Executive Anne Savage said publication of the Guidelines marked the beginning of Australia's next challenge.

"Developing world-class Guidelines is only half the task. Now we must ensure they are implemented.

"Evidence only saves lives when it reaches the men who need it. Australian men need to understand their individual risk, know when to have the conversation with their GP, and be supported by clinicians with access to the latest evidence.

"These Guidelines provide Australia with an extraordinary opportunity to reduce deaths from our most commonly diagnosed cancer. Realising that opportunity will require coordinated implementation, clinician education, consumer awareness, and ongoing investment in evidence-based care.

"If we get implementation right, future generations of Australian men will look back on these Guidelines as the moment Australia fundamentally changed its approach to prostate cancer early detection."

Prostate cancer is Australia's most commonly diagnosed cancer, with almost 29,000 Australian men expected to be diagnosed this year and almost 4,000 expected to die from the disease.

Around 300,000 Australian men are currently living after a diagnosis of prostate cancer. The new Guidelines identify early detection as a national health priority and provide the evidence-based framework to support earlier diagnosis while continuing to minimise unnecessary harms.

ENDS

For information and support, call 1800 22 00 99 to speak with a Prostate Cancer Specialist Nurse or email telenurse@pcfa.org.au.

Click here to download the full guidelines.

Editor's notes

Key changes in the 2026 Guidelines include:

  • A modern risk-based framework for prostate cancer early detection.
  • Updated recommendations for men with significant family history and inherited genetic risk.
  • Contemporary guidance supporting the routine use of multiparametric MRI before biopsy.
  • Greater emphasis on shared decision-making between men and their clinicians.
  • Updated recommendations supporting active surveillance for appropriate low-risk cancers.
  • New guidance for high-risk men and priority populations.
  • A framework designed to detect clinically significant prostate cancer earlier while continuing to minimise unnecessary harms.

 

About prostate cancer in Australia

  • Nearly 29,000 Australian men are diagnosed each year.
  • Nearly 4,000 Australian men die annually from prostate cancer.
  • Around 300,000 Australian men are alive today following a prostate cancer diagnosis.
  • Men with a family history face double the risk of diagnosis.
  • Men living in regional and remote Australia experience poorer outcomes and a 24% increased risk of death compared to men in metropolitan areas.